These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 22548227)
21. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. Nallamothu BK; Shojania KG; Saint S; Hofer TP; Humes HD; Moscucci M; Bates ER Am J Med; 2004 Dec; 117(12):938-47. PubMed ID: 15629733 [TBL] [Abstract][Full Text] [Related]
22. Contrast-induced nephropathy and mortality: possible crucial role of asymmetric dimethylarginine. Andreotti F; Santucci E; Coluzzi G J Cardiovasc Med (Hagerstown); 2007 Dec; 8(12):1043. PubMed ID: 18163017 [No Abstract] [Full Text] [Related]
23. [Animal experiment study for evaluation of endothelial damage to the aorta after contrast medium administration by ioxithalamate and iomeprol. Quantitative detection of increased cell proliferation with autoradiography]. Gabelmann A; Weyrich G; Aurich M; Haberstroh J; Freudenberg N; Langer M Rontgenpraxis; 1995 Jan; 48(1):14-7. PubMed ID: 7871436 [No Abstract] [Full Text] [Related]
24. A review of contemporary prevention strategies for radiocontrast nephropathy: a focus on fenoldopam and N-acetylcysteine. Lepor NE Rev Cardiovasc Med; 2003; 4 Suppl 1():S15-20. PubMed ID: 12556733 [TBL] [Abstract][Full Text] [Related]
25. Correlation between tubulointerstitial nephropathy and glomerular lesions induced by adriamycin. Güezmes A; Fernández F; Garijo F; Val-Bernal F Nephron; 1992; 62(2):198-202. PubMed ID: 1436314 [TBL] [Abstract][Full Text] [Related]
26. Investigating the volume status before contrast nephropathy studies. Toprak O; Cirit M Nephrol Dial Transplant; 2005 Feb; 20(2):464; author reply 464-6. PubMed ID: 15673702 [No Abstract] [Full Text] [Related]
27. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. Ozcan EE; Guneri S; Akdeniz B; Akyildiz IZ; Senaslan O; Baris N; Aslan O; Badak O Am Heart J; 2007 Sep; 154(3):539-44. PubMed ID: 17719303 [TBL] [Abstract][Full Text] [Related]
28. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury. Drager LF; Andrade L; Barros de Toledo JF; Laurindo FR; Machado César LA; Seguro AC Nephrol Dial Transplant; 2004 Jul; 19(7):1803-7. PubMed ID: 15128882 [TBL] [Abstract][Full Text] [Related]
29. N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best? Shalansky SJ; Vu T; Pate GE; Levin A; Humphries KH; Webb JG Pharmacotherapy; 2005 Aug; 25(8):1095-103. PubMed ID: 16207100 [TBL] [Abstract][Full Text] [Related]
30. Is there enough evidence to support use of N-acetylcysteine in contrast-induced nephropathy? Gonzales DA; Star RA; Kern SJ; Natanson C; Danner RL Ann Intern Med; 2008 Aug; 149(3):213-4; author reply 215-6. PubMed ID: 18678852 [No Abstract] [Full Text] [Related]
31. Contrast-induced nephropathy: a clinical and evidence-based approach. Tepel M; Aspelin P; Lameire N Circulation; 2006 Apr; 113(14):1799-806. PubMed ID: 16606801 [No Abstract] [Full Text] [Related]
32. [Can the nephroprotective effect of N-acetylcysteine be optimized?]. Barrios V; Escobar C; Echarri R Rev Esp Cardiol; 2010 Apr; 63(4):501-2. PubMed ID: 20334824 [No Abstract] [Full Text] [Related]
33. Is there enough evidence to support use of N-acetylcysteine in contrast-induced nephropathy? Trivedi H Ann Intern Med; 2008 Aug; 149(3):213; author reply 215-6. PubMed ID: 18678853 [No Abstract] [Full Text] [Related]
34. Is there enough evidence to support use of N-acetylcysteine in contrast-induced nephropathy? Ferrante G; Locca D; Barlis P Ann Intern Med; 2008 Aug; 149(3):214-5; author reply 215-6. PubMed ID: 18678854 [No Abstract] [Full Text] [Related]
35. Is there enough evidence to support use of N-acetylcysteine in contrast-induced nephropathy? Berwanger O Ann Intern Med; 2008 Aug; 149(3):215; author reply 215-6. PubMed ID: 18678855 [No Abstract] [Full Text] [Related]
36. Prevention of contrast-induced nephropathy: an overview. Ellis JH; Cohan RH Radiol Clin North Am; 2009 Sep; 47(5):801-11, v. PubMed ID: 19744595 [TBL] [Abstract][Full Text] [Related]
37. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). ACT Investigators Circulation; 2011 Sep; 124(11):1250-9. PubMed ID: 21859972 [TBL] [Abstract][Full Text] [Related]
38. Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics. Coyle LC; Rodriguez A; Jeschke RE; Simon-Lee A; Abbott KC; Taylor AJ Am Heart J; 2006 May; 151(5):1032.e9-12. PubMed ID: 16644332 [TBL] [Abstract][Full Text] [Related]
39. Contrast medium-induced nephropathy: strategies for prevention. Massicotte A Pharmacotherapy; 2008 Sep; 28(9):1140-50. PubMed ID: 18752385 [TBL] [Abstract][Full Text] [Related]
40. Contrast media nephropathy: in depth review. Hussain N; Al Otaibi T; Nampoory MR Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):174-82. PubMed ID: 18310863 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]